Dr. Elizabeth Yeu discusses the prevalence of keratoconus among refractive surgery candidates and how to best diagnose keratoconus based on clinical signs and conventional exams. She also discusses genetic testing for keratoconus and preemptive testing indications.
This activity is supported by an unrestricted educational grant from Avellino, AcuFocus, and Glaukos.
Upon completion of this activity, the participant should be able to:
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Evolve Medical Education designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Elizabeth Yeu, MD
Virginia Eye Consultants
Medical Director, CVP Mid-Atlantic
Cornea, Cataract, External Disease, and Refractive Surgery
Assistant Professor
Department of Ophthalmology
Eastern Virginia Medical School
Norfolk, VA
Gerd U. Auffarth, MD, PhD, FEBO
Chairman, Department of Ophthalmology, Heidelberg University Eye Hospital
Director (Head), International Vision Correction Research Centre
Director (Head), David J. Apple Center for Ocular Pathology
University-Eye Clinic
Heidelberg, Germany
Brandon D. Ayres, MD
Cornea Service
Wills Eye Hospital
Philadelphia, PA
Nicole Fram, MD
Managing Partner, Advanced Vision Care
Clinical Instructor of Ophthalmology
Stein Eye Institute, UCLA
Los Angeles, CA
Richard Lindstrom, MD
Program Director
Founder and Attending Surgeon
Minnesota Eye Consultants
Minneapolis, Minnesota
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Elizabeth Yeu, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Advanced Vision Group, Alcon, Allergan, Avellino, Bausch + Lomb, BioTissue, BVI, BlephEx, Bruder, Carl Zeiss Meditec, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Glaukos, Guidepoint, Johnson & Johnson Vision, Kala Pharmaceuticals, LayerBio, Lensar, Melt, Merck, Mynosys, Novartis, Ocular Science, Ocusoft, Omeros, Oyster Point Pharmaceuticals, Science Based Health, Sight Sciences, Sun Pharmaceutical Industries, Surface, Tarsus, TearLab, Thea, TopCon, and Visus. Research/Grants: Alcon, BioTissue, Johnson & Johnson Vision, Tarsus, TopCon, and TearLab. Stock/Shareholder: Advanced Vision Group, Avellino, BlephEx, CorneaGen, Expert Opinion, LayerBio, Mati, Melt, Modernizing Medicine, Ocular Science, Orasis, Oyster Point Pharmaceuticals, Staar, Tarsus, and Visus.
Gerd U. Auffarth, MD, PhD, FEBO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Carl Zeiss Meditec, Johnson & Johnson Vision. Lecture Fees: Biotech, Carl Zeiss Meditec, Johnson & Johnson Vision, Hoyga, Kowa, Oculentis, Oculus, Rayner, Santen, and Sifi. Travel Fees: Alcon Vision, Carl Zeiss Meditec, Johnson & Johnson Vision, Hoya, Kowa, Oculentis, Rayner, Santen, and Sifi. Research Grants: Acufocus, Johnson & Johnson Vision, Anew, Biotech, Carl Zeiss Meditec, Contamac, Hoya, Kowa, Oculentis, Oculus, PhysIOL, Rayner, Santen, and Sifi.
Brandon D. Ayres, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon Vision, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Dompé, Eyevance, Eyepoint Pharmaceuticals, Glaukos, Gore Surgical, Kala, Omeros, Microsurgical Technology, Mojo, Novartis, Sight Sciences, and TearLab. Speaker’s Bureau: Alcon Vision, Allergan, and Dompé.
Nicole Fram, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Carl Zeiss Meditec, CorneaGen, Johnson & Johnson Vision, Ocular Therapeutix, Orasis Pharmaceuticals, and Oyster Point. Speaker's Bureau: Alcon, Beaver-Visitec, CorneaGen, and Glaukos. Stock/Shareholder: CorneaGen, Ocular Science, and Orasis Pharmaceuticals. Research/Grants: Carl Zeiss Meditec and Ocular Therapeutix.
Richard Lindstrom, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Stock/Shareholder: Acufocus.
The Evolve and The Fundingsland staff and planners have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, Acufocus, or Glaukos.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Eric D. Donnenfeld, MD
Marjan Farid, MD
Jason J. Jones, MD
Eva I. Liang, MD, FACS
Carlton Yuen, MD
